GCIA
RVNC

Gabelli & Co Investment Advisers’s Revance Therapeutics, Inc. RVNC Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,058,500
Closed -$3.22M – 285
2024
Q4 		$3.22M Buy
1,058,500
+218,700
+26% +$953K 0.55% 46
2024
Q3 		$4.36M Buy
+839,800
New +$4.17M 0.74% 41

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Gabelli & Co Investment Advisers's RVNC Position: Q1 2025 in Review

Gabelli & Co Investment Advisers sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,058,500 shares — an estimated $3.22M sold.

Gabelli & Co Investment Advisers first reported a position in RVNC in Q3 2024 and held it in 2 quarters. The position peaked at $4.36M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • Gabelli & Co Investment Advisers reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 1,058,500 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $3.22M.
  • Gabelli & Co Investment Advisers first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 2 quarters.
  • Gabelli & Co Investment Advisers's Revance Therapeutics, Inc. position peaked at $4.36M in Q3 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2025, filed 14 May 2025.